Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

olis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

P-LLY

ALIMTA(R) (pemetrexed for injection), Lilly

GEMZAR(R) (gemcitabine HCl for injection), Lilly

This press release contains forward-looking statements about the potential of ALIMTA for the treatment of non-small cell lung cancer and reflects Lilly's current beliefs. However, as with any pharmaceutical products under development, there are substantial risks and uncertainties in the process of development, commercialization, and regulatory review. There is no guarantee that the product will receive additional regulatory approvals. There is also no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

ALIMTA ABBREVIATED PRESCRIBING INFORMATION

Uses

ALIMTA is indicated in combination with cisplatin for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. ALIMTA is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, after prior chemotherapy.

Dosage and Administration

The drug is to be administered intravenously, under the supervision of a physician qualified in the use of cytotoxic anti-cancer therapy.

Malignant pleural mesothelioma: Pemetrexed in combination with cisplatin has been investigated using a three-week (21-day) cycle. Pemetrexed is used at 500 mg/m(squared) of body surface area (BSA), given by ten-minute infusion, on day 1 of each 21-day cycle. Cisplatin is used at 75 mg/m(squared) BSA, given by two-hour infusion, approximately 30 minutes after completion of the pemetrexed infusion on day 1 of each cycle. Adequate anti-emetic treatment and hydrat
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... New England Journal of Medicine ( NEJM ) ... the investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib ... small lymphocytic lymphoma (SLL). Ibrutinib was shown to be ... SLL, even in patients who were at high-risk due ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... LONG BRANCH, N.J., March 1, 2011 Pharma ChemOutsourcing today ... member companies of the USA,s various state biotechnology associations to ... would like to attend the September 12-15 show in New ... of hundreds of successful biotechnology companies over the past 12 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced that ... Citi 2011 Global Health Care Conference on Thursday, March ... New York Hotel in New York City. Cowen and ... 2011 at 4:45 p.m. Eastern Time at The Boston Marriott ...
Cached Medicine Technology:Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey 2Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2
(Date:6/19/2013)... 2013 Chrysler made news recently when it ... 2.7 million Jeeps. The Jeep models in question are the ... according to the NHTSA are vulnerable to fire and explosion ... models are rear-mounted and have been alleged to catch fire ... Grand Cherokee with 32 rear-end crashes, which resulted in 44 ...
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... has increased its health budget by over 30 percent ... a new medical college//. ,"In a bid to ... medical education department budget to about Rs.1.52 billion. This ... billion," an official said. ,"The government not ...
... the June Journal of the American Society of Nephrology ... for chronic renal failure//. ,"Our results confirm an ... as an important causative factor in kidney disease," comments ... of the new study. ,Dr. Ejerblad and colleagues ...
... According to a new study by New York University School ... New York City are severely infected// with hepatitis B virus. ... the liver gets inflamed and can ultimately lead to cirrhosis ... 12 issue of Morbidity and Mortality Weekly, published by the ...
... new study, oral and intravenous antiviral drug may be ... ,Shingles, which is caused by varicella-zoster virus, is a ... at the University of Colorado and Health Sciences Center ... three women with moderate to severe pain following shingles. ...
... Middle school students have expressed a high degree of comfort ... schools are safer// , and make the students feel wanted. ... other schools. Psychologists from UCLA and UC ... than 70 sixth-grade classrooms in 11 Los Angeles public middle ...
... which is a severe form of food poisoning, now has ... team of researchers working at the University of Bristol//. ... researchers have narrowed down on a particular antibiotic called fosfomycin, ... effective in the laboratory, this drug has never been considered ...
Cached Medicine News:Health News:Kidney Failure three times pronounced with obesity 2Health News:Asian American Community Prone To Hepatitis B infection 2Health News:Asian American Community Prone To Hepatitis B infection 3Health News:Comfort Level, Maximum in Ethnically Diverse Schools 2Health News:Comfort Level, Maximum in Ethnically Diverse Schools 3
Indications For Usage: , Nasal surgery. , Ophthalmic surgery. , Facial surgery. , T&A surgery. ...
The Cuffed Endoflex endotracheal tube had a murphy eye, high volume, low pressure cuff., ,Endoflex endotracheal tubes are individual packaged in sterilized pouches, 10 units per box, 10 boxes pe...
... The new Level 1 H-1200 Fast Flow ... builds on the benefits of the existing Level ... Level 1 H-1200 Fast Flow Fluid Warmer incorporates ... clamping capability, while continuing to deliver warm fluids ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
Medicine Products: